MitoImmune Therapeutics Inc.
- Home
- Companies
- MitoImmune Therapeutics Inc.
- Products
- Model MIT-001 - Allogenic Hematopoietic ...
Model MIT-001 - Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
MIT-001 is an innovative clinical candidate that blocks the root cause of graft-versus-host disease, which often occurs during allogenic hematopoietic stem cell transplantation (HSCT), through a mechanism of action that is differentiated from any current treatment.
Most popular related searches
hematopoietic stem cell transplant
stem cell transplant
stem cell transplantation
hematopoietic stem
cell therapy
stem cell
hematopoietic cells
hematopoietic cell
immune cell
allogeneic cell
Description(Graft-versus-host disease, GvHD)
- After HSCT, donated immune cells attack the host body
- GvHD occurs in 25~65% of HSCT patients, a major cause of death rate increase
- There are different forms of GvHD that arise depending on the time of onset